Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Feasibility: Recruitment rate
Timeframe: 3 years
Feasibility: CAV event rate
Timeframe: 3 years
Feasibility: Treatment cross over rate
Timeframe: 3 years
Feasibility: Loss to follow up rate
Timeframe: 3 years
Feasibility: Compliance to treatment
Timeframe: 3 years